3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Hepatocellular
26
Colorectal Neoplasms
9
Neoplasms
7
Carcinoma, Renal Cell
7
Pancreatic Neoplasms
5
Neoplasm Metastasis
5
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Liver Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Melanoma
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Medullary
2
Wilms Tumor
1
Thrombocytosis
1
Sarcoma, Kaposi
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrence
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Interventions
Gemcitabine
11
pembrolizumab
10
Oxaliplatin
7
Nivolumab
7
Irinotecan
7
Fluorouracil
7
Capecitabine
7
durvalumab
6
Sorafenib
6
Leucovorin
6
Cyclophosphamide
6
Paclitaxel
5
Ipilimumab
5
tislelizumab
3
poly ICLC
3
lenvatinib
3
fludarabine
3
Sunitinib
3
Radiotherapy
3
Cisplatin
3
Cetuximab
3
130-nm albumin-bound paclitaxel
3
seocalcitol
2
selinexor
2
pemigatinib
2
futuximab
2
fludarabine phosphate
2
donafenib
2
cemiplimab
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
cabozantinib
×
Gastrointestinal
×
Clear all
NCT03755791
2025-12-11
COSMIC-312
Exelixis
Phase 3
Active not recruiting
837 enrolled
14 charts